Pharmaceutical

ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML

A Phase III trial with the drug has shown improved molecular response rates compared to standard of care therapies in CML.

Jun 2, 2024 - 04:00
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
A Phase III trial with the drug has shown improved molecular response rates compared to standard of care therapies in CML.
Read the original article

Tags:

Previous Article

Key opinion leaders on unmet needs in amyotrophic lateral sclerosis

Next Article

Compound medication pharmacies and companies 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Value-based payments are making it harder to see your primary care doctor on short notice

Opinion: Value-based payments are making it harder to s...

Sep 20, 2023

Panbela obtains rights to develop and commercialise Flynpovi to treat FAP

Panbela obtains rights to develop and commercialise Fly...

Apr 12, 2023

M&A in pharmaceutical in Singapore increased in Q2 2023

Jul 27, 2023